PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28842253-0	2017	Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERalpha-positive breast cancer cells.	Letrozole	53-62	estrogen receptor 1	Homo sapiens	14-18	
28842253-0	2017	Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERalpha-positive breast cancer cells.	Letrozole	53-62	estrogen receptor 1	Homo sapiens	77-84	
28842253-1	2017	Transcriptional silencing of estrogen receptor alpha (ERalpha) expression is an important etiology contributing to the letrozole-resistance in ERalpha-positive breast cancer (BCa) cells, but the transcription factors responsible for this transcriptional repression remain largely unidentified.	Letrozole	119-128	estrogen receptor 1	Homo sapiens	29-52	
28842253-1	2017	Transcriptional silencing of estrogen receptor alpha (ERalpha) expression is an important etiology contributing to the letrozole-resistance in ERalpha-positive breast cancer (BCa) cells, but the transcription factors responsible for this transcriptional repression remain largely unidentified.	Letrozole	119-128	estrogen receptor 1	Homo sapiens	54-61	
28842253-1	2017	Transcriptional silencing of estrogen receptor alpha (ERalpha) expression is an important etiology contributing to the letrozole-resistance in ERalpha-positive breast cancer (BCa) cells, but the transcription factors responsible for this transcriptional repression remain largely unidentified.	Letrozole	119-128	estrogen receptor 1	Homo sapiens	143-150	
28842253-4	2017	Mechanistically, MYOD was shown to be a potent corepressor of ESR1 transcription, and this transcriptional repression was significantly enhanced in the presence of letrozole treatment.	Letrozole	164-173	estrogen receptor 1	Homo sapiens	62-66